<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165268</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-066</org_study_id>
    <nct_id>NCT01165268</nct_id>
  </id_info>
  <brief_title>Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the&#xD;
      renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin</measure>
    <time_frame>Before 7 days of oral administration of 10 mg of dapagliflozin</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin</measure>
    <time_frame>After 7 days of oral administration of 10 mg of dapagliflozin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Splay of the glucose titration curve</measure>
    <time_frame>Before 7 days of oral administration of 10 mg of dapagliflozin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Splay of the glucose titration curve</measure>
    <time_frame>After 7 days of oral administration of 10 mg of dapagliflozin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin</measure>
    <time_frame>Study Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin</measure>
    <time_frame>Study Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin (T2DM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin (Healthy Subjects)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 10 mg, Once daily, 7 days</description>
    <arm_group_label>Dapagliflozin (Healthy Subjects)</arm_group_label>
    <arm_group_label>Dapagliflozin (T2DM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for T2DM&#xD;
&#xD;
          -  Diagnosis of T2DM&#xD;
&#xD;
          -  Must be on one of the following therapies: diet therapy alone, diet plus a&#xD;
             sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin&#xD;
&#xD;
          -  Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2&#xD;
             months prior to study drug administration&#xD;
&#xD;
          -  Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10%&#xD;
&#xD;
        Inclusion criteria for healthy subjects:&#xD;
&#xD;
          -  Healthy subjects (as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, ECGs, and clinical laboratory determinations)&#xD;
&#xD;
        Inclusion criteria for all subjects:&#xD;
&#xD;
          -  Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion &lt; 300&#xD;
             mg/g creatinine)&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 38 kg/m²&#xD;
&#xD;
          -  Men and women, ages 18 to 65 years, inclusive&#xD;
&#xD;
        Exclusion criteria for all subjects:&#xD;
&#xD;
          -  Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Subjects with T2DM with fasting plasma glucose &gt; 200 mg/dL, healthy subjects with&#xD;
             fasting plasma glucose &gt; 105 mg/dL&#xD;
&#xD;
          -  Subjects with T2DM with HbA1C &gt; 10.0%, healthy subjects with HbA1C &gt; 6.8%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute For Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3651&amp;filename=MB102-066_CSR_synopsis.pdf</url>
    <description>MB102-066_CSR_synopsis</description>
  </link>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

